These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 33240439)
1. Insight updating of the molecular hallmarks in ovarian carcinoma. Mota A; S Oltra S; Moreno-Bueno G EJC Suppl; 2020 Aug; 15():16-26. PubMed ID: 33240439 [TBL] [Abstract][Full Text] [Related]
2. Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer. Roque R; Ribeiro IP; Figueiredo-Dias M; Gourley C; Carreira IM Biology (Basel); 2024 Jan; 13(2):. PubMed ID: 38392306 [TBL] [Abstract][Full Text] [Related]
3. Identification of Novel Somatic Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665 [TBL] [Abstract][Full Text] [Related]
6. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma. Wallbillich JJ; Morris RT; Ali-Fehmi R Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500 [TBL] [Abstract][Full Text] [Related]
7. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368 [TBL] [Abstract][Full Text] [Related]
8. miR-7 expression in serous ovarian carcinomas. Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828 [TBL] [Abstract][Full Text] [Related]
10. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G Cells; 2019 Jun; 8(6):. PubMed ID: 31197119 [TBL] [Abstract][Full Text] [Related]
12. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Kieffer Y; Bonneau C; Popova T; Rouzier R; Stern MH; Mechta-Grigoriou F Front Genet; 2020; 11():219. PubMed ID: 32256521 [TBL] [Abstract][Full Text] [Related]
13. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53. Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283 [TBL] [Abstract][Full Text] [Related]
16. Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets. De A; De A; Sharma R; Suo W; Sharma M J Cancer; 2020; 11(7):1927-1939. PubMed ID: 32194804 [No Abstract] [Full Text] [Related]
18. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315 [TBL] [Abstract][Full Text] [Related]
19. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Liu G; Yang D; Sun Y; Shmulevich I; Xue F; Sood AK; Zhang W Pharmacogenomics; 2012 Oct; 13(13):1523-35. PubMed ID: 23057551 [TBL] [Abstract][Full Text] [Related]